NCT01361217View on ClinicalTrials.gov

The Effects of Multiple Dose Fluoxetine and Metabolites on CYP1A2, CYP2C19, CYP2D6 and CYP3A4 Activity

NACompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

June 30, 2012

Study Completion Date

June 30, 2012

Conditions
Drug-Drug InteractionHealthy Volunteers
Interventions
DRUG

Fluoxetine, Lovastatin, Omeprazole, caffeine, midazolam, dextromethorphan

"1x20mg oral fluoxetine capsules by mouth daily on Study Day 5, then 3x20mg fluoxetine capsules by mouth daily on Study Days 6 through 18.~On study day 1 and study day 18, 100mg caffeine, 2mg midazolam, 30mg dextromethorphan and 20mg omeprazole (enteric coated formulation) orally with 250mL of water.~On study day 3 and study day 20 20mg of lovastatin with 250mL of water."

All Listed Sponsors
collaborator

National Institute of General Medical Sciences (NIGMS)

NIH

lead

University of Washington

OTHER

NCT01361217 - The Effects of Multiple Dose Fluoxetine and Metabolites on CYP1A2, CYP2C19, CYP2D6 and CYP3A4 Activity | Biotech Hunter | Biotech Hunter